Viking Therapeutics, Inc.
VKTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$24.40
KIRA · Stoqly’s AI analyst, in plain words
- Viking Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
- Viking Therapeutics, Inc. lost $360M in fiscal 2025.
Market cap
$2.8B
P/E
—
Revenue
$0.0M
Net income
−$360M
Free cash flow
—
Operating margin
—
Viking Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$360M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Viking Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 11, 2026
- Legal name
- Viking Therapeutics, Inc.
- CIK
- 0001607678
Viking Therapeutics, Inc. · VKTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$55.0M | −$68.9M | −$85.9M | −$110M | −$360M |
| Diluted EPS | −$0.71 | −$0.90 | −$0.91 | −$1.01 | −$3.19 |
| Cash | |||||
| Cash from operations | −$47.6M | −$48.4M | −$73.4M | −$87.8M | −$279M |
| Share buybacks | — | $6.8M | — | — | — |
| Share count change | 6.3% | −0.5% | 22.8% | 15.6% | 3.3% |
| Debt and strength | |||||
| Cash and short-term investments | $202M | $155M | $362M | $903M | $706M |
| Shareholders' equity | $202M | $145M | $348M | $880M | $639M |
| Current ratio | 24.0x | 7.6x | 19.2x | 33.1x | 9.3x |
| Returns and quality | |||||
| Return on equity | −24.6% | −39.7% | −34.8% | −17.9% | −47.3% |
| Return on tangible equity | −27.2% | −47.4% | −24.7% | −12.5% | −56.3% |
| Piotroski F-score | 2 | 2 | 3 | 3 | 1 |
| Altman Z'' | 25.2 | 3.8 | 19.2 | 36.4 | 7.1 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$20.1M
4 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Viking Therapeutics, Inc. · VKTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $24.40 a share, the company is worth $2.8B.
Source: SEC EDGAR XBRL filings (CIK 0001607678). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.